X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (257) 257
Publication (67) 67
Book Review (21) 21
Patent (6) 6
Book Chapter (2) 2
Conference Proceeding (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (105) 105
male (82) 82
female (81) 81
index medicus (80) 80
middle aged (71) 71
hematology (64) 64
aged (62) 62
adult (60) 60
oncology (55) 55
rituximab (47) 47
antineoplastic combined chemotherapy protocols - therapeutic use (42) 42
treatment outcome (40) 40
prognosis (36) 36
chemotherapy (35) 35
lymphomas (30) 30
disease-free survival (28) 28
therapy (28) 28
engineering sciences (23) 23
non-hodgkins-lymphoma (23) 23
retrospective studies (23) 23
aged, 80 and over (22) 22
neoplasm staging (21) 21
animals (20) 20
antineoplastic combined chemotherapy protocols - adverse effects (19) 19
aerogels (18) 18
follow-up studies (18) 18
cancer (17) 17
survival (17) 17
analysis (16) 16
antineoplastic combined chemotherapy protocols - administration & dosage (16) 16
biochemistry & molecular biology (16) 16
cyclophosphamide - administration & dosage (16) 16
young adult (16) 16
[ spi.energ ] engineering sciences [physics]/domain_spi.energ (15) 15
adolescent (15) 15
disease (15) 15
domain_spi.energ (15) 15
doxorubicin - administration & dosage (15) 15
vincristine - administration & dosage (15) 15
lymphoma (14) 14
lymphoma, large b-cell, diffuse - drug therapy (14) 14
prednisone - administration & dosage (14) 14
silica (14) 14
survival analysis (14) 14
aerogel (13) 13
care and treatment (13) 13
chemistry (13) 13
recurrence (13) 13
survival rate (13) 13
antibodies, monoclonal - administration & dosage (12) 12
cyclophosphamide (12) 12
lymphoma, large b-cell, diffuse - mortality (12) 12
alzheimer's disease (11) 11
antibodies, monoclonal, murine-derived (11) 11
antibodies, monoclonal, murine-derived - administration & dosage (11) 11
doxorubicin (11) 11
fluorodeoxyglucose f18 (11) 11
medicine & public health (11) 11
patients (11) 11
prospective studies (11) 11
[ spi.mat ] engineering sciences [physics]/materials (10) 10
b-cell lymphoma (10) 10
cell biology (10) 10
drug administration schedule (10) 10
italy (10) 10
kaplan-meier estimate (10) 10
lymphoma, non-hodgkin - drug therapy (10) 10
materials (10) 10
positron-emission tomography (10) 10
radiotherapy (10) 10
toxicity (10) 10
abridged index medicus (9) 9
alzheimers-disease (9) 9
antineoplastic agents - therapeutic use (9) 9
biophysics (9) 9
cellulose (9) 9
hemic and lymphatic diseases (9) 9
lymphoma, follicular - pathology (9) 9
lymphoma, large b-cell, diffuse - pathology (9) 9
mice (9) 9
positron-emission-tomography (9) 9
predictive value of tests (9) 9
transplantation (9) 9
chop (8) 8
combined modality therapy (8) 8
doxorubicin - therapeutic use (8) 8
drug therapy (8) 8
fdg-pet (8) 8
follicular lymphoma (8) 8
lymphoma, follicular - mortality (8) 8
lymphoma, non-hodgkin - mortality (8) 8
materials science, ceramics (8) 8
materials science, multidisciplinary (8) 8
olive oil (8) 8
polyphenols (8) 8
trial (8) 8
antibodies, monoclonal, murine-derived - therapeutic use (7) 7
chemistry, physical (7) 7
diagnosis (7) 7
drying (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Mediterranean Journal of Hematology and Infectious Diseases, ISSN 2035-3006, 06/2012, Volume 4, Issue 1, pp. e2012044 - e2012044
Patients with chronic immune thrombocytopenia treated with romiplostim may benefit from a higher starting dose when a rapid increase in count is needed, but it... 
ITP | romiplostim: platelet count
Journal Article
Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 8, pp. 950 - 956
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2018, Volume 29, Issue 3, pp. 707 - 714
Journal Article
Mediterranean journal of hematology and infectious diseases, 2012, Volume 4, Issue 1, p. e2012044
Patients with chronic immune thrombocytopenia treated with romiplostim may benefit from a higher starting dose when a rapid increase in count is needed, but it... 
Journal Article
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, ISSN 1619-7070, 01/2012, Volume 39, Issue 1, pp. 4 - 12
Purpose The use of early (interim) PET restaging during first-line therapy of Hodgkin's lymphoma (HL) in clinical practice has considerably increased because... 
FDG-PET | RESPONSE CRITERIA | 3 CYCLES | PROGNOSTIC SCORE | FDG PET scan | ABVD | Chemotherapy | POSITRON-EMISSION-TOMOGRAPHY | THERAPY | DISEASE | Early response to treatment | SCAN | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Hodgkin's lymphoma
Journal Article
British Journal of Haematology, ISSN 0007-1048, 08/2017, Volume 178, Issue 4, pp. 588 - 591
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2014, Volume 32, Issue 17, pp. 1769 - 1775
Purpose To assess the role of [F-18] fluorodeoxyglucose ([F-18] FDG) positron emission tomography/computed tomography (PET/CT) after rituximab and... 
NON-HODGKINS-LYMPHOMA | ONCOLOGY | PET | CHEMOTHERAPY
Journal Article
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2014, Volume 20, Issue 24, pp. 6398 - 6405
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9700, pp. 1512 - 1520
Summary Background Chemotherapy with high-dose methotrexate is the conventional approach to treat primary CNS lymphomas, but superiority of polychemotherapy... 
Internal Medicine | DEFERRED RADIOTHERAPY | MEDICINE, GENERAL & INTERNAL | B-CELL LYMPHOMA | INTERNATIONAL WORKSHOP | RESPONSE CRITERIA | EUROPEAN ORGANIZATION | CONSOLIDATING RADIOTHERAPY | NON-HODGKINS-LYMPHOMA | INITIAL TREATMENT | CENTRAL-NERVOUS-SYSTEM | CEREBROSPINAL-FLUID | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Lymphoma, Non-Hodgkin - radiotherapy | Cranial Irradiation - methods | Central Nervous System Neoplasms - radiotherapy | Adult | Lymphoma, Non-Hodgkin - drug therapy | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Combined Modality Therapy | Remission Induction | Methotrexate - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Cytarabine | Patient outcomes | Central nervous system diseases | Dosage and administration | Lymphomas | Drug therapy, Combination | Methotrexate | Drug therapy | Data analysis | Disease | Monoclonal antibodies | Data collection | Radiation therapy | Patients | Tropical diseases | Index Medicus | Abridged Index Medicus
Journal Article
PLOS ONE, ISSN 1932-6203, 03/2013, Volume 8, Issue 3
The presence of amyloid aggregates of the 42 amino acid peptide of amyloid beta (A beta 42) in the brain is the characteristic feature of Alzheimer's disease... 
CAENORHABDITIS-ELEGANS | ALZHEIMERS-DISEASE | MEDITERRANEAN DIET | MULTIDISCIPLINARY SCIENCES | BILOBA EXTRACT EGB-761 | MOLECULAR PATHOLOGY | VIRGIN OLIVE OIL | COGNITIVE IMPAIRMENT |